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A B S T R A C T
Summary: The EEG background activity reﬂects the functional state of the brain. The established
sensitivity of EEG to drug intoxication and in particular to antiepileptic drugs (AEDs) made that EEG has
become useful as an objective measure for monitoring chronic AED therapy and in investigation of
cognitive functions. Therapywith classical AEDs has become associatedwith slowing of EEG background
rhythm and the EEG changes correlated to changes on cognitive measures. So far, it has not been tested
whether the relatively new AED, levetiracetam (LEV) has a detrimental effect on the EEG background
frequencies, too.
Methods: During the time of 6 months 28 patients underwent EEG-recording and neuropsychological
testing at the three timepoints: before initiating LEV therapy, after 2 months and again after 4 months
after achieving plateau dosing of LEV. EEG background frequency was analysed by using the fast Fourier
Transform (FFT).
Results: The titration and the following treatment with LEV add-on showed no negative effect on any of
the measures analysed. In particular it did not lead to the lower peak frequency within the alpha band, it
neither decreased the percentage of alpha band nor increase the percentage of theta and delta band. In
addition there could be noticed an increase of the percentage of beta band.
Conclusions: Our ﬁndings demonstrate, that a LEV add-on therapy is not associated with a slowing of the
EEG background frequency. This is in accordance with neuropsychological reports of our own lab and
others showing that LEV add-on therapy has no negative effects on cognitive functions, either.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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EEG slowing is generally considered to indicate central nervous
system (CNS) dysfunction, for example as the consequence of
ischaemic, metabolic or toxic conditions.1,2 All medications that
inﬂuence CNS can also lead to changes of EEG frequency, in
particular of EEG background frequency. Background slowing can
be used as a neurophysiological parameter of drug impact on
cerebral functions.3
Antiepileptic drugs (AEDs) are among the most widely
prescribed CNS active medications. The fact that most patients
remain on therapy for many years and often for a lifetime,
emphasises the need to focus on long-term adverse effects of these
drugs. Alteration of cognitive functions is one of the major factors
inﬂuencing quality of life in patients with epilepsy.4,5 Neuropsy-
chological testing has been the preferred method of examining
cognitive functions related to the use of AEDs but it has a number* Corresponding author at: Gerhart-Hauptmann-Strasse 8, 18435 Stralsund,
Germany. Tel. +49 3831 282853.
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1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.02.001of methodological problems, for example a signiﬁcant test–retest
variability or a low speciﬁcity (the results may be inﬂuenced by
other factors such as mood, anxiety, less sleep, pain).5
The established sensitivity of EEG to antiepileptic drugs made
that EEG has become useful as an objectivemeasure formonitoring
chronic AED therapy and in investigation of cognitive functions.6,3
The EEG effects of older, classical AEDs are well known: a stable
therapy with, for example, Phenytoin (PHT), Carbamazepine (CBZ),
Phenobarbital (PB) enhances a slow activity on EEG background
rhythm (increase of theta and delta, decrease of alpha frequency)
and the EEG changes correlate to changes on cognitivemeasures.7–9
Within the last two decades several new AEDs have been
introduced into clinical practice. Most of them are at least so
effective as the old AEDs, but they seem to be better tolerated, in
particular regarding cognitive functions than the old drugs.10,1
Recent studies have also examined the EEG effect of the new
AEDs—it seems to bemilder and less consistent than that caused by
old AEDs. For example, lamotrigine with no or minimal cognitive
side effect does not induce EEG background slowing.11 On the
other side topiramate, that is known for its neurotoxic adverse
effects, increase slow, theta and delta and decrease rapid
frequencies within alpha and beta band.12,13vier Ltd. All rights reserved.
Table 2
Results for the quantitative EEG measures within analysed parameters at the three
timepoints T1, T2, and T3.
Parameters N Mean Median Minimum Maximum
Max.Alpha1 22 9.50 9.51 7.25 12.88
Max.Alpha2 22 9.52 9.25 7.50 12.50
Max.Alpha3 15 9.79 9.75 7.50 12.75
Rel.Alpha1 22 0.58 0.61 0.22 0.83
Rel.Alpha2 22 0.55 0.56 0.18 0.80
Rel.Alpha3 15 0.53 0.50 0.26 0.77
Rel.Theta1 22 0.14 0.13 0.04 0.38
Rel.Theta2 22 0.13 0.09 0.04 0.35
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into the clinical practice in Europe for about 8 years. This drug is
known for its favourable neuropsychological proﬁle, but it
can also cause adverse behavioural side effects such as
adynamia or aggression.14,15 In contrast to other new AED,
the impact of LEV on the EEG background activity has not been
investigated so far.
The subjects that have been included to the following study
underwent a neuropsychological testing before and during the LEV
therapy, prior to the performed EEG. Thereby no cognitive deﬁcits
could be observed; moreover, some of the functions, for example
learning and language understanding, demonstrated signiﬁcant
beneﬁts in the course of LEV therapy.16
We raised the question, whether neurophysiologic parameters
would reﬂect these positive cognitive results observed under LEV




Twenty-eight consecutive unselected patients with pharma-
coresistent epilepsy were recruited from the outpatient clinic from
the Epilepsy Center Berlin Brandenburg, Teaching Hospital of the
Humboldt University, Berlin (Table 1). At the beginning of the
study they had a stable basic co-medicationwith an AED (except of
3 patients that were untreated at the entry), to which in the course
of the study LEV was added.
In this study we included the 22 patients with monotherapy at
the beginning.
During the individual study period of 6 months patients
underwent EEG-recording and neuropsychological testing at three
timepoints: T1, before initiating LEV therapy (baseline); T2, two
months after the initiation of therapy and achieving the end-dose
(titration phase); T3, four months after achieving plateu dosing of
LEV (plateu phase). The end-dose was adjusted for each patient
individually, depending on seizure control and tolerability andwas
between 1000 and 3000 mg/day. The co-medication remained
unchanged during the entire study.
2.2. Procedure
EEG-recordings were held after neuropsychological testing at
rest with closed eyes at 2:00 p.m. The whole recordings were
obtained over 4–6 min. We attempted to maintain subjects in an
alert but relaxed state (simple mental activation is the best
condition for EEG background rhythm), so during the registration
they were asked for two minutes a few simple questions. For the
study we considered this 2-min-activation-phase only.
EEG was recorded with golden electrodes placed according to
the international 10–20-system at F7, F8, T3, T4, T5, T6, O1, and O2.
Electrode impedances was less than 5 kV.
In 15 patients EEG-recordingwas performed at three points (T1,
T2, and T3); in 7 patients only twice (T1 and T2).Table 1
Characteristic of the patients, N = 28.
Sex, F/M 19/9
IQ (kris. intelligence) 100 (S.D. = 12), range 79–125
Type of epilepsy Focal = 23
Idiopathic. gen. = 4
Not sure = 1
Duration of disease 13,02 (S.D. = 10.38) range 1–46
AED therapy at entry VPA = 11, CBZ = 6, OXC = 2, LTG = 2,
GBP = 1, VPA + ESM = 1, OXC + TPX = 1,
PRM + TPX = 1, no AEDs at baseline = 3The occipital EEG rhythms from each record were investigated
bymeans of quantitative analysis, using the fast Fourier Transform
(FFT).
For further EEG processing we chose the methods that have
been proposed and published by Salinsky et al.17 Prior to analysis
the 2-min-segments of activation EEG were selected. The EEG
segments with artifacts or with interictal epileptiform activity
(Spikes or Sharp waves) were eliminated. Thirty 4-s epochs of
EEG (120 s of activation) were analysed by using the FFT. In order
to minimize the statistical variables, the analysis was limited to
the O1 and O2 electrodes, and the results from both were
averaged.
The following parameters from the FFT were considered: (a)
peak frequency within the alpha band; (b) percentage of total
power (relative power) within the alpha band; (c) percentage of
total power within the theta band; (d) percentage of total power
within the delta band; (e) percentage of total power within the
beta band.
2.3. Statistics
A Friedman test was used to compare the quantitative EEG
measures in the group of patients, who underwent EEG-recordings
at the three timepoints (T1, T2, and T3).
A Wilcoxon test was used for pair comparisons of EEG results
between the three timepoints.
A p-value <0.05 was considered signiﬁcant. All procedures
were performed with SPSS 11.
3. Results
The results show that a titration and than a 6-month treatment
with LEV add-on therapy did not lead to slowing of EEG rhythms
over occipital regions.
Within the analysed parameters we observed:
(a) no decrease in peak alpha frequency, no lower percentage of
total power within the alpha band after initiating and in course
of LEV therapy. There was an upward tendency of maximal
alpha frequency within the analysed three timepoints, which
was statistically not signiﬁcant.
(b) no power increase within the slower, theta and delta activities.Rel.Theta3 15 0.13 0.11 0.04 0.39
Rel.Delta1 22 0.11 0.10 0.03 0.23
Rel.Delta2 22 0.14 0.09 0.03 0.42
Rel.Delta3 15 0.11 0.08 0.04 0.34
Rel.Beta1 22 0.15 0.14 0.03 0.27
Rel.Beta2 22 0.15 0.13 0.05 0.28
Rel.Beta3* 15 0.19 0.14 0.04 0.36
Abbreviations: Max.Alpha = Maximal Alpha Frequency, Rel.Alpha = Relative Power
for Alpha Band, Rel.Theta = Relative Power for Theta Band, Rel.Delta = Relative
Power for Delta Band, Rel.Beta = Relative Power for Beta Band. The numbers 1, 2,
and 3 correspond to three time points: T1, baseline; T2, titration phase; T3, plateu
phase.
* Signiﬁcantly different at p < 0.05.
Fig. 1. Graphical presentation (boxplot-diagrams) of the results for each analysed parameter at the three timepoints.
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which was statistically signiﬁcant (p = 0.027 at p < 0.05).
The following study demonstrates that the therapy with LEV
exert no negative effect on any of the measures analysed. The
results for each of the analysed parameter are presented in Table 2.
The graphic presentation of the results follows in Fig. 1.
4. Discussion
Our study is the ﬁrst to investigate the impact of LEV add-on
therapy on EEGbackground frequency. So far, it has not been tested
whether the titration and the following therapy with LEV induces
changes, in particular slowing of EEG background.
The ﬁndings from our study demonstrate that a LEV add-on
therapy have no negative effect on EEG frequencies over occipital
region. We did not ﬁnd a slowing of occipital frequency: in the
course of LEV therapy it came neither to decrease of alpha
frequency nor to increase of theta and delta activity.
The results from our quantitative EEG analyse are comparable
with these, that were reported under a LTG therapy. Both
medications did not lead to EEG changes within the alpha, theta
and delta band, but increased the percentage of beta band. Both
medications belong to AEDs which do not induce cognitive
dysfunctions.11,18
The relationship between EEG and mental processes is a
complex problem. The systemic studies in particular of Salinsky
et al., Meador et al., Herkes et al., Frost et al. demonstrated an
association between the elecktoencephalographical changes (in
particular of EEG background rhythm) and the changes in cognitive
functions.1,6,7,19 There have been reported a positive correlation
between the slowing of EEG background rhythm and the negative
neuropsychological results on the cognitive test batteries: greater
the EEG slowing, greater the cognitive dysfunction and subjective
neurotoxicity. In addition, Salinsky et al. have demonstrated that
the EEG slowing could better reﬂect the AED-induced subjective
neurotoxicity than the objective cognitive test batteries.Asmentioned above the electrophysiological impact of LTG and
LEV is different than that caused by classical AEDs. According to
Marciani et al. the LTG induced increase of faster EEG activity could
be indicative of a positive drug role in attentional processes.18 For
Neufeld et al. these EEG changes observed under LTG therapy were
analogous to those of increased alertness on neuropsychological
testing.12
The reports from our neuropsychological lab and the others
indicated that LEV has no negative effects on cognitive func-
tions.16,20 So far were our EEG results in accordance with the
cognitive performances. Further, some of the cognitive functions
on our testing showed improvements. Why we have not observed
thereby an increase in the alpha activity, as could be eventual
assumed? As Salinsky et al. have already reported there is no direct
or casual relation between EEG background measures and
cognitive functions3 and the improvement of cognitive functions
is not closely correlated to an increase of background frequency.
The other possible explanation, could be the fact, that the all our
patients were treated, beside LEV, with the other AED, so the
pharmacokinetic interaction of co-medications could eventual
inhibit the positive EEG effect of titrated LEV. It is known that the
polytherapy and the high-dose of AEDs can exert greater EEG
effect. Miyauchi et al. and Clemens et al. reported that the most
marked EEG slowing by epileptic patients was in the polytherapy
group, followed by themonotherapy group and then the untreated
group.21,22 However, the fact that the untreated epilepsy group,
compared to normal controls, also showed the background slowing
suggests that not only AEDs can play here a role. It seems that the
epilepsy per se may be also involved in the genesis of the EEG
background slowing by patients with epilepsy. The factors that
could be by this process relevant and contribute to EEG back-
ground abnormalities by epileptic patients are the presence of
structural or functional brain, high frequency of seizures, seizure
onset at young ages (0–5 years).18,20
Our study has several limitations. We have not had a control
group. The sample of the patients was small and treated with
different co-medications to which LEV was added. Different AEDs
J. Veauthier et al. / Seizure 18 (2009) 392–395 395have different effects on EEG background frequency (as have been
mentioned in the introduction), so this could false the ‘‘real’’ effect
of LEV. This issue could be resolved by a LEV monotherapy study.
During the performance of the present study, treatment with LEV
was admitted only as an add-on therapy. In the meantime also a
LEV monotherapy has been authorised in a clinical practice. The
possible effects of a LEV monotherapy on EEG background
frequency and cognition have to be determined.
Overall quantitative EEG analysis seems to be a simple, fast and
reliable method to monitoring neurotoxicity and in investigation
of cognitive functions. It is recommendable to use itmore often in a
clinical practice in patients on chronic AED therapy.
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